Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/262138
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study |
Autor: | Muro, Antonio; Belhassen-García, Moncef; Muñoz Bellido, Juan Luís; Lorenzo Juanes, Helena; Vicente, Belén; Pendones, Josué; Adserias, José; Sánchez Hernández, Gonzalo; Rodríguez Rosa, Miguel; Vicente-Villardón, J. L.; Burguillo, Javier; López Andaluz, Javier; Martín Oterino, José Ángel; García-Criado, Francisco Javier; Barbero, Fausto; Morales, Ana I.; Galindo-Villardón, Purificación; González-Sarmiento, Rogelio CSIC ORCID | Palabras clave: | SARS-CoV-2 COVID-19 Antibodies Seroprevalence Screening University Salamanca Spain |
Fecha de publicación: | 2021 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Journal of Clinical Medicine 10(15): 3214-3214 (2021) | Resumen: | [Background]: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. [Objective]: The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. [Methodology]: The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July–October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. Principal findings: A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (p = 0.006). Based on the questionnaire, loss of smell and fever were the symptoms most strongly associated with seropositivity, and 22.6% of seropositive participants were asymptomatic. Social distancing was the most effective hygiene measure (p = 0.0007). There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (p = 0.0000), but not between students who lived in private homes and those who lived in dormitories. IgG antibodies decreased over time in the participants with confirmed self-reported COVID-19 diagnoses. [Conclusions]: The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures. |
Descripción: | © 2021 by the authors | Versión del editor: | http://dx.doi.org/10.3390/jcm10153214 | URI: | http://hdl.handle.net/10261/262138 | DOI: | 10.3390/jcm10153214 | E-ISSN: | 2077-0383 |
Aparece en las colecciones: | (IBMCC) Artículos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Seroprevalence of SARS-CoV-2_Muro_PV_Art2021.pdf | 2,29 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
1
checked on 01-abr-2024
SCOPUSTM
Citations
1
checked on 17-abr-2024
WEB OF SCIENCETM
Citations
2
checked on 26-feb-2024
Page view(s)
65
checked on 19-abr-2024
Download(s)
91
checked on 19-abr-2024